1-(1-Isopropyl-cyclopropyl)-2-methyl-propan-1-one | 61406-21-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-Isopropyl-cyclopropyl)-2-methyl-propan-1-one
• 英文别名: 2-Methyl-1-[1-(propan-2-yl)cyclopropyl]propan-1-one；2-methyl-1-(1-propan-2-ylcyclopropyl)propan-1-one
• CAS: 61406-21-1
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: DXBKDDHPHGKYOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  trans-1,2-Diisopropyl-cyclobutan-1,2-diol 生成 1-(1-Isopropyl-cyclopropyl)-2-methyl-propan-1-one
  参考文献：
  名称：

  Barnier,J.-P.; Conia,J.-M., Bulletin de la Societe Chimique de France, 1976, p. 285 - 290

  摘要：

  DOI：

文献信息

• PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
  申请人：Huang Taisheng

  公开号：US20110224190A1

  公开（公告）日：2011-09-15

  The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  本发明提供了哌啶-4-基氮杂环丙烷衍生物，以及它们的组合物和使用方法，这些衍生物调节Janus激酶1（JAK1）的活性，并且在治疗与JAK1活性相关的疾病方面具有用处，例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
• Azetidinone Derivatives and Methods of Use Thereof
  申请人：Aslanian G. Robert

  公开号：US20080076751A1

  公开（公告）日：2008-03-27

  The present invention relates to Azetidinone Derivatives, compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

  本发明涉及吲哚酮衍生物，包含吲哚酮衍生物的组合物以及治疗或预防脂质代谢紊乱、疼痛、糖尿病、血管疾病、脱髓鞘病或非酒精性脂肪肝病的方法，包括向患者投予有效量的吲哚酮衍生物。
• Spirocyclic Azetidinone Compounds and Methods of Use Thereof
  申请人：Burnett Duane A.

  公开号：US20080070890A1

  公开（公告）日：2008-03-20

  The present invention relates to Spirocyclic Azetidinone Compounds, compositions comprising a Spirocyclic Azetidinone Compound and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of a Spirocyclic Azetidinone Compound.
• US20140275031A1
  申请人：——

  公开号：US20140275031A1

  公开（公告）日：2014-09-18
• US7202246B2
  申请人：——

  公开号：US7202246B2

  公开（公告）日：2007-04-10